Oplunofusp

奥伦诺芙普

Report date: 2026/03/31 20:00:21

Base Information

Drug NameOplunofusp
Drug Alias NameParaDaseFludaseRecombinant sialidase fusion protein (Ansun Biopharma)DAS-181-F02DAS181-F04 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionVirus internalization inhibitors
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lower Respiratory Tract InfectionsBronchiectasis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAnsun Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNitto Avecia Pharma Services IncAnsun Biopharma Inc
Inactive CompaniesIqvia Rds (Shanghai) Co LtdNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lower Respiratory Tract InfectionsParamyxoviridae Infections +[4] 
Inactive IndicationsBronchiectasisAsthma

Other Information

ATC CodeN/A
Related LinksN/A